Family-centered Care for Sick Newborns: A Thumbnail View

Family-centered care (FCC) for sick newborns is emerging as a paradigmatic shift in the practice of facility-based newborn care. It seeks to transforming a provider-centered model into a client-centered one and thus build a new therapeutic alliance. FCC is the cornerstone of continuum of care, imparting caregiving competencies to parents/caregivers both within institutions as well as after the discharge. This has potential gains for the newborn, family members, and facility-level staff. The initial model piloted in tertiary-care settings is now undergoing translation at five sites across the country; the outcomes are keenly awaited.     

Research on medication use in the neonatal intensive care unit

Introduction: Research on medication use aims at assessing how much of current pharmacotherapy is rational. In neonates, this is hampered by extensive off-label drug use and limited knowledge.

Areas covered: We report on medication use research and have conducted a systematic review of observational studies on medication use to provide an updated overview on characteristics, objectives, methods, and patterns in hospitalized neonates. Moreover, a review on aspects of medication use for opioids, anti-epileptics, gastric acid-related disorders and respiratory stimulants with emphasis on trends and impact of interventions is presented, illustrating how research on medication use can contribute to improved neonatal pharmacotherapy and more focused research. Medication use reports describe patterns and provide signals on irrational use, benchmarking, or can guide research priorities. Moreover, this may generate information on how neonatal health topics and their pharmacotherapy are handled over time or across regions.

Expert opinion: Research on medicine utilization is relevant, since it will inform us on aspects like trends, variability, or about the impact and pattern of implementation of guidelines in neonates. Further progress necessitates to merge datasets on medication use with clinical characteristics, and perinatal drug use remains an area in need of additional research.     

正常婴儿肺动脉血流特征及解剖学原理分析

目的 应用超声多普勒技术测量正常婴儿肺动脉主干及左右肺动脉血流速度,并初步探讨其可能的机理.方法 使用GE Vivid7超声诊断仪检查60例正常新生儿,分别检测1周、1个月、6个月及1年时主动脉内径AOD;肺动脉主干内径MPA及血流速度Pv,左、右肺动脉内径LPA、RPA及血流速度LPv、RPv,并计算LPA RPA/AO.结果 1周时左、右肺动脉速度高于肺动脉主干速度,且以右肺动脉明显,1周后左、右肺动脉血流速度逐渐减慢,1年后均基本低于肺动脉主干内血流速度,肺动脉主干血流速度及LPA RPA/AO比例在1周、1个月、6个月及1年组差异无统计学意义.结论 正常新生儿左、右肺动脉血流速度较高,随生长、发育肺动脉血流速度逐渐降低直至正常.     

脐血铅水平与妊娠结局及影响因素的关系

目的 :了解本地区脐血铅水平现状及其妊娠结局与妊娠并发症 ,新生儿体格发育及神经行为发育的关系 ,并探讨脐血铅与环境因素的关系。方法 :采用 HB2 10 0原子吸收光谱仪用原子吸收法测定 178例经剖宫分娩的新生儿脐带血水平 ,同时观察孕妇妊娠与分娩期有无合并症与并发症 ,并于新生儿出生后即刻测量体重、身长 ,2 4 h内测量头围、胸围和腹围 ,采用神经行为发育量表 ,对出生后 4 2 d的 5 0例婴儿进行神经行为发育评分。同时对产妇家庭环境等相关因素进行问卷调查。结果 :178例脐血铅最高值 12 2 μg/ L,最低值 1μg/ L,中位数 36 μg/ L,脐血铅≥ 10 0 μg/ L 者 6例 ,占3.33%。脐血铅水平与妊娠并发症无明显相关性 ,与新生儿体格发育及神经行为发育评分无明显相关性。新生儿血铅水平与环境因素 (家庭住址、居室新旧、家庭经济情况、职业等 )差异有显著性 ,P<0 .0 5。结论 :本组脐血铅水平与孕期并发症及新生儿体格发育及神经行为发育评分无明显关系。脐血铅水平与环境因素有关。     

新生儿Rh溶血病不同血源换血疗法的疗效观察

目的:探讨新生儿 Rh溶血病实行换血疗法时的血源选择和换血量的确定。方法 :选取在我院接受换血治疗的 6 3例 Rh溶血病患儿 ,其中用 Rh阳性血换血 32例 ,Rh阴性血换血 31例 ,分析其换血前后血清总胆红素(TB)和血红蛋白 (Hb)变化以判断疗效。 结果 :两种换血术均获得满意疗效 ,换血后胆红素值明显下降 ,所有患儿均痊愈出院。 结论 :在紧急情况下 ,若无法及时得到 Rh阴性血 ,可用 Rh阳性血换血 ,换血量至少应 >2 0 0 m l/ kg(为 Rh阴性血的 2倍 ) ,若应用得当 ,是一项安全有效的替代疗法     

新生儿骨矿质含量及影响因素的研究

应用双光子及单光子吸收测定技术，检测了９２名出生３ｄ内的新生儿骨矿质含量，其中巨大儿３０名，正常体重儿３２名，低出生体重儿３０名，其孕龄分别是４０．１±０．７、３９．１±１．５和３７．４±１．２孕周。结果表明，巨大儿、正常体重儿、低出生体重儿的全身骨矿质含量分别是１０１．６±２８．８、８５．２±１９．８、５９．９±２７．２ｇ／ｃｍ２，巨大儿骨矿质含量最高，正常体重儿次之，低出生体重儿最低，差异有显著性（Ｐ＜０．０１）。颅骨、肱骨、股骨的骨矿质含量与全身的骨矿质含量有高度的相关性，相关系数分别是０．９４３、０．８７９和０．７４５（Ｐ＜０．０１）。全身的骨矿质含量与出生体重、孕龄及头围有高度相关性，相关系数分别是０．７５５、０．５９６和０．５５６（Ｐ＜０．０１）。提示颅骨、肱骨及股骨的任一部位均可代表全身的骨矿质含量，肱骨是确定全身骨矿质含量较好的部位，新生儿骨矿质含量受出生体重、孕龄及头围的影响较大。     

Arachidonic acid metabolites in CSF in hypoxic-ischaemic encephalopathy of newborn infants

The aim of this study was to evaluate the cerebral synthesis of eicosanoids in the asphyctic newborn and to investigate the relation between the prostanoid profiles in cerebrospinal fluid (CSF) and the appearance and severity of hypoxic-ischaemic encephalopathy (HIE). Levels of 6-keto-PGF _1-α, TXB₂, PGE₂ and PGF_2-α in CSF were measured in 40 full term newborns during the first day of life. Thirty of these newborns had birth asphyxia and were divided into three groups: 10 without HIE, 12 with mild HIE and 8 with moderate-severe HIE. They were compared to a control group of 10 non-hypoxic newborns. Determinations of the metabolites in CSF were performed by RIA and expressed as pg/ml (mean ± SD). The CSF TXB₂ (thromboxane A₂ metabolite) in asphyxiated newborns was always higher than in the control group (28.12 ± 10.6), and related to the severity of HIE ( p = 0:005): without HIE (50.84 ± 16.4; p = 0:02), mild HIE (80.65 ± 12.64; p ± 0:01) and moderate-severe HIE (178.14 ± 20.5; p < 0:01). The CSF 6-keto-PGF _1-α (prostacyclin metabolite) in asphyxiated newborns was always higher than in the control group (80.55 ± 12.56), but indirectly related to the severity of HIE: without HIE (240.95 ± 28.12; p < 0:01), mild HIE (183.65 ± 30.1; p < 0:01) and moderate-severe HIE (140.55 ± 25.12; p < 0:01). In the moderate-severe HIE group, the increase in TXB₂ was higher than the rise in 6-keto-PGF _1-α.